Got additional information colleagues shared in Twitter.
Thread with some comparisons with #ACTT1
#IDtwitter 1/
![](https://pbs.twimg.com/media/Eav9LXbUYAArc-9.jpg)
But these days the Supplementary Appendices in trial reports have additional relevant information:
nejm.org/doi/full/10.10…
#DontCoverDiscover
Caveat is that ~30% of the study patients had not completed follow up to day 28, curves flatten after day 21
![](https://pbs.twimg.com/media/EawCoDOUEAAATwW.jpg)
Population on high-flow/non-invasive ventilation small, so not included
![](https://pbs.twimg.com/media/EawD0q2VAAEV0Ok.jpg)
![](https://pbs.twimg.com/media/EawD0q2U0AA0eNt.jpg)
![](https://pbs.twimg.com/media/EawD0q1VAAAwtKD.jpg)
Interesting stuff to ponder. Some space for you to think about it...
![](https://pbs.twimg.com/media/EawEcsYUMAATwr1.jpg)
#ACTT1 did restrict patients with significant renal dysfunction and high LFTs but may not explain it all.
![](https://pbs.twimg.com/media/EawGRpgVcAAEai2.jpg)
But not sure if a trend test is a appropriate when you go from protection to harm (cross RR=1)
May be better to use #remdesivir first in this severity band first if you have access
![](https://pbs.twimg.com/media/EawIHVrVAAAZjJa.jpg)
![](https://pbs.twimg.com/media/EawINBDU4AEQUOo.jpg)
The #ACTT1 KM curve shows a small #remdesivir benefit initially, but then the curves cross.
Can't wait for the final report!
![](https://pbs.twimg.com/media/EawJObBU8AAktxt.jpg)
![](https://pbs.twimg.com/media/EawJSJgU4AAVDvt.jpg)
I also did a comparison of Day 14 KM estimates between trials in this table, which are complete
![](https://pbs.twimg.com/media/EawLOfCUMAEGEBo.jpg)
The Day 14 KM mortality estimates for the #RECOVERYtrial were done using graphs from a source that remains anonymous, but all data numbers correspond to what has been posted online.